SELLAS Life Sciences Group Inc buy melinda
Start price
09.11.18
/
50%
€101.93
Target price
13.11.18
€162.36
Performance (%)
-9.73%
End price
13.11.18
€92.01
Summary
This prediction ended on 13.11.18 with a price of €92.01. With a performance of -9.73%, the BUY prediction for SELLAS Life Sciences Group Inc by melinda closed slightly in the red. melinda has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
SELLAS Life Sciences Group Inc | 1.799% | 1.799% | -28.984% | -87.107% |
iShares Core DAX® | 1.518% | 3.456% | 25.970% | 21.597% |
iShares Nasdaq 100 | 1.240% | 2.983% | 31.325% | 39.177% |
iShares Nikkei 225® | 2.808% | 2.743% | 19.597% | 5.115% |
iShares S&P 500 | 0.403% | 2.187% | 28.624% | 40.348% |
Comments by melinda for this prediction
In the thread SELLAS Life Sciences Group Inc diskutieren
SecteurProduits pharmaceutiques
Develop biopharmaceuticals
SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutic for a broad range of indications.
Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein.
The company was founded on April 3, 2006 and is headquartered in New York, NY.
SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutic for a broad range of indications.
Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein.
The company was founded on April 3, 2006 and is headquartered in New York, NY.
Nombre d'employés : 11 personnes.
(Vom Mitglied beendet)
Stopped prediction by melinda for SELLAS Life Sciences Group Inc
SELLAS Life Sciences Group Inc
Start price
Target price
Perf. (%)
€1.72
08.09.20
08.09.20
€2.00
04.11.21
04.11.21
386.91%
05.11.21
05.11.21
SELLAS Life Sciences Group Inc
Start price
Target price
Perf. (%)
€62.24
15.10.18
15.10.18
€135.30
07.11.18
07.11.18
22.75%
07.11.18
07.11.18
SELLAS Life Sciences Group Inc
Start price
Target price
Perf. (%)
€47.36
31.08.18
31.08.18
€90.20
01.10.18
01.10.18
12.38%
01.10.18
01.10.18
SELLAS Life Sciences Group Inc
Start price
Target price
Perf. (%)
€9,389.8
30.06.16
30.06.16
€27,060
19.07.16
19.07.16
16.22%
19.07.16
19.07.16